# A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)

> **NCT06360354** · PHASE1 · RECRUITING · sponsor: **Amgen** · enrollment: 350 (estimated)

## Conditions studied

- Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers

## Interventions

- **DRUG:** Anvumetostat
- **DRUG:** Gemcitabine
- **DRUG:** Nab-paclitaxel
- **DRUG:** Modified FOLFIRINOX
- **DRUG:** RMC-6236

## Key facts

- **NCT ID:** NCT06360354
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-29
- **Primary completion:** 2027-02-26
- **Final completion:** 2029-02-25
- **Target enrollment:** 350 (ESTIMATED)
- **Last updated:** 2026-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06360354

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06360354, "A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06360354. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*